06:03 PM EST, 11/25/2025 (MT Newswires) -- Myriad Genetics ( MYGN ) entered a partnership with Clairity and MagView to roll out an integrated artificial intelligence platform for breast cancer risk assessment across the US, the companies said late Tuesday.

Patients will benefit from an integrated view of genotype through Myriad's MyRisk hereditary cancer test and phenotype using Clairity Breast within MagView's Luminary Risk platform workflow, helping to identify more women at high risk for breast cancer.

The platform is expected to provide clinicians with actionable insights that help develop personalized treatment plans, according to a statement.